AJ 503
Alternative Names: AJ-503Latest Information Update: 24 Feb 2021
At a glance
- Originator AnnJi Pharmaceutical
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Atopic dermatitis; Psoriasis
Most Recent Events
- 01 Feb 2021 Early research in Atopic dermatitis in Taiwan (PO) before February 2021 (AnnJi Pharmaceutical pipeline, February 2021)
- 01 Feb 2021 Early research in Psoriasis in Taiwan (PO) before February 2021 (AnnJi Pharmaceutical pipeline, February 2021)